Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
110.10
+2.85 (2.66%)
At close: Oct 31, 2025, 4:00 PM EDT
107.90
-2.20 (-2.00%)
After-hours: Oct 31, 2025, 7:54 PM EDT
Spruce Biosciences Employees
Spruce Biosciences had 21 employees as of December 31, 2024. The number of employees decreased by 8 or -27.59% compared to the previous year.
Employees
21
Change (1Y)
-8
Growth (1Y)
-27.59%
Revenue / Employee
$61,857
Profits / Employee
-$2,301,810
Market Cap
62.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21 | -8 | -27.59% |
| Dec 31, 2023 | 29 | 2 | 7.41% |
| Dec 31, 2022 | 27 | 12 | 80.00% |
| Dec 31, 2021 | 15 | -2 | -11.76% |
| Dec 31, 2020 | 17 | 2 | 13.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SPRB News
- 26 days ago - Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
- 26 days ago - This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barrons
- 27 days ago - Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 6 weeks ago - Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - Business Wire